AAPL   269.30 (-1.54%)
FB   188.63 (-0.59%)
MSFT   159.42 (+0.78%)
AMZN   1,856.80 (-1.46%)
CGC   18.11 (-1.79%)
NVDA   263.93 (+4.49%)
BABA   202.31 (-1.33%)
GE   10.24 (-1.44%)
TSLA   657.04 (-3.23%)
AMD   44.70 (+1.57%)
ACB   1.37 (-5.52%)
F   6.82 (-2.15%)
NFLX   365.14 (-1.77%)
BAC   28.18 (-3.26%)
DIS   115.68 (-2.00%)
AAPL   269.30 (-1.54%)
FB   188.63 (-0.59%)
MSFT   159.42 (+0.78%)
AMZN   1,856.80 (-1.46%)
CGC   18.11 (-1.79%)
NVDA   263.93 (+4.49%)
BABA   202.31 (-1.33%)
GE   10.24 (-1.44%)
TSLA   657.04 (-3.23%)
AMD   44.70 (+1.57%)
ACB   1.37 (-5.52%)
F   6.82 (-2.15%)
NFLX   365.14 (-1.77%)
BAC   28.18 (-3.26%)
DIS   115.68 (-2.00%)
AAPL   269.30 (-1.54%)
FB   188.63 (-0.59%)
MSFT   159.42 (+0.78%)
AMZN   1,856.80 (-1.46%)
CGC   18.11 (-1.79%)
NVDA   263.93 (+4.49%)
BABA   202.31 (-1.33%)
GE   10.24 (-1.44%)
TSLA   657.04 (-3.23%)
AMD   44.70 (+1.57%)
ACB   1.37 (-5.52%)
F   6.82 (-2.15%)
NFLX   365.14 (-1.77%)
BAC   28.18 (-3.26%)
DIS   115.68 (-2.00%)
AAPL   269.30 (-1.54%)
FB   188.63 (-0.59%)
MSFT   159.42 (+0.78%)
AMZN   1,856.80 (-1.46%)
CGC   18.11 (-1.79%)
NVDA   263.93 (+4.49%)
BABA   202.31 (-1.33%)
GE   10.24 (-1.44%)
TSLA   657.04 (-3.23%)
AMD   44.70 (+1.57%)
ACB   1.37 (-5.52%)
F   6.82 (-2.15%)
NFLX   365.14 (-1.77%)
BAC   28.18 (-3.26%)
DIS   115.68 (-2.00%)
Log in

NASDAQ:SRNE - Sorrento Therapeutics Stock Price, Forecast & News

$2.12
-0.06 (-2.76 %)
(As of 02/28/2020 12:15 PM ET)
Today's Range
$2.08
Now: $2.12
$2.30
50-Day Range
$2.18
MA: $3.48
$4.79
52-Week Range
$1.39
Now: $2.12
$6.50
Volume3.29 million shs
Average Volume4.24 million shs
Market Capitalization$354.90 million
P/E RatioN/A
Dividend YieldN/A
Beta3.04
Sorrento Therapeutics, Inc, a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SRNE
CUSIPN/A
Phone858-203-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.19 million
Book Value$1.70 per share

Profitability

Net Income$-203,540,000.00
Net Margins-1,101.69%

Miscellaneous

Employees382
Market Cap$354.90 million
Next Earnings Date3/20/2020 (Estimated)
OptionableOptionable

Receive SRNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SRNE and its competitors with MarketBeat's FREE daily newsletter.


Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Sorrento Therapeutics.

What price target have analysts set for SRNE?

3 brokers have issued twelve-month price objectives for Sorrento Therapeutics' stock. Their forecasts range from $12.00 to $30.00. On average, they anticipate Sorrento Therapeutics' stock price to reach $21.00 in the next year. This suggests a possible upside of 876.7% from the stock's current price. View Analyst Price Targets for Sorrento Therapeutics.

What is the consensus analysts' recommendation for Sorrento Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sorrento Therapeutics.

Has Sorrento Therapeutics been receiving favorable news coverage?

Media coverage about SRNE stock has been trending extremely negative on Friday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sorrento Therapeutics earned a media sentiment score of -4.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Sorrento Therapeutics.

Who are some of Sorrento Therapeutics' key competitors?

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Novavax (NVAX), Amarin (AMRN), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Cara Therapeutics (CARA), Alibaba Group (BABA) and Exelixis (EXEL).

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the folowing people:
  • Dr. Henry H. Ji, Co-Founder, Chairman, CEO & Pres (Age 55)
  • Dr. Jerome Bernard Zeldis, Chief Medical Officer & Pres of Clinical Devel. (Age 69)
  • Mr. George K. Ng, Corp. Sec. (Age 45)
  • Mr. Jiong Shao M.B.A., CFA, Exec. VP & CFO (Age 51)
  • Ms. Deborah H. Telman, Sr. VP & Gen. Counsel

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.36%), Geode Capital Management LLC (1.02%), Bank of New York Mellon Corp (0.24%), Charles Schwab Investment Management Inc. (0.19%), Alliancebernstein L.P. (0.16%) and Barclays PLC (0.13%). Company insiders that own Sorrento Therapeutics stock include Abg Management Ltd and George K Ng. View Institutional Ownership Trends for Sorrento Therapeutics.

Which institutional investors are selling Sorrento Therapeutics stock?

SRNE stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Bank of America Corp DE, Integrated Wealth Concepts LLC, Bank of New York Mellon Corp and Matrix Asset Advisors Inc. NY. View Insider Buying and Selling for Sorrento Therapeutics.

Which institutional investors are buying Sorrento Therapeutics stock?

SRNE stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Goldman Sachs Group Inc., Barclays PLC, Alliancebernstein L.P., California Public Employees Retirement System, Virtu Financial LLC, UBS Group AG and Credit Suisse AG. View Insider Buying and Selling for Sorrento Therapeutics.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $2.15.

How big of a company is Sorrento Therapeutics?

Sorrento Therapeutics has a market capitalization of $360.77 million and generates $21.19 million in revenue each year. The biopharmaceutical company earns $-203,540,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Sorrento Therapeutics employs 382 workers across the globe.View Additional Information About Sorrento Therapeutics.

What is Sorrento Therapeutics' official website?

The official website for Sorrento Therapeutics is http://www.sorrentotherapeutics.com/.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-203-4100 or via email at [email protected]


MarketBeat Community Rating for Sorrento Therapeutics (NASDAQ SRNE)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  510 (Vote Outperform)
Underperform Votes:  319 (Vote Underperform)
Total Votes:  829
MarketBeat's community ratings are surveys of what our community members think about Sorrento Therapeutics and other stocks. Vote "Outperform" if you believe SRNE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRNE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel